Thermo Fisher acquires Phitonex

By The Science Advisory Board staff writers

January 4, 2021 -- Thermo Fisher Scientific has completed its acquisition of Phitonex, a North Carolina-based company that has created a spectral dye platform for high-resolution biology applications.

Phitonex's Phiton platform is designed to speed up cell therapy, immuno-oncology, and immunology research and development. The platform acts as a structure to maintain a greater number of fluorescent dyes in specific ways, allowing researchers to obtain more comprehensive cell sample data. It also allows researchers to quickly create multiple different dye labels to increase the number of proteins and cell populations identified in a single experiment.

The acquisition will allow Thermo Fisher to provide greater flow cytometry and imaging multiplexing capabilities for protein and cell analysis research needs. Phitonex's product offering is also a natural expansion of the company's existing protein and cell analysis portfolio, according to Thermo Fisher.

Financial details of the acquisition were not disclosed.

Thermo Fisher expands plasmid manufacturing capabilities
Thermo Fisher Scientific announced it will build a new plasmid DNA manufacturing facility in Carlsbad, CA.
Thermo Fisher unveils new isotopic mass spectrometry system
Thermo Fisher has announced it has designed a new high-resolution mass spectrometry system for accurately extracting isotopic data from very small samples.
Thermo Fisher partners with Northeastern University
Thermo Fisher Scientific and Northeastern University have partnered to advance analytical capabilities and boost the biopharmaceutical industry.
Thermo Fisher expands collaboration with Symphogen
Thermo Fisher Scientific has expanded its collaboration with Symphogen to support that company's efforts to provide therapeutic proteins for biopharmaceutical...
Thermo Fisher expands Direct-to-Patient clinical trial service
Thermo Fisher Scientific said it has expanded its Direct-to-Patient clinical trial service to enable clinical trial medications to be delivered directly...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter